Shares of DaVita Inc. (NYSE:DVA – Get Rating) have earned an average recommendation of “Hold” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $130.50.
A number of research firms have issued reports on DVA. Truist Financial reduced their target price on shares of DaVita from $125.00 to $110.00 in a research note on Friday, May 6th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 5th.
Several institutional investors have recently modified their holdings of the company. Johnson Financial Group Inc. acquired a new stake in DaVita during the fourth quarter valued at $27,000. CI Investments Inc. acquired a new stake in shares of DaVita in the third quarter worth about $34,000. Parkside Financial Bank & Trust lifted its position in shares of DaVita by 88.6% in the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock worth $35,000 after buying an additional 147 shares during the last quarter. CWM LLC lifted its position in shares of DaVita by 154.1% in the first quarter. CWM LLC now owns 432 shares of the company’s stock worth $49,000 after buying an additional 262 shares during the last quarter. Finally, Monolith Advisors acquired a new stake in shares of DaVita in the fourth quarter worth about $51,000. 87.47% of the stock is owned by institutional investors and hedge funds.
DaVita (NYSE:DVA – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported $1.61 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.24). DaVita had a net margin of 7.78% and a return on equity of 78.24%. The business had revenue of $2.82 billion during the quarter, compared to analyst estimates of $2.89 billion. The company’s quarterly revenue was down .1% on a year-over-year basis. During the same period last year, the firm posted $2.09 earnings per share. As a group, research analysts predict that DaVita will post 7.79 earnings per share for the current fiscal year.
About DaVita (Get Rating)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
- Beware The Rebound In Home Depot
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.